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Introduction
Dementia occurs in up to 80% of Parkinson's disease (PD) subjects when followed longitudinally. [1] [2] [3] Current treatments for PD dementia (PDD) may improve cognitive and behavioural symptoms, 4 but have no effect on disease progression.
The pathophysiology of PDD is poorly understood and may vary between individuals, but evidence from clinical 5 and pathological studies [6] [7] [8] [9] [10] [11] indicate that amyloid-β (Aβ), neurofibrillary tangle pathology and cortical Lewy body (LB) deposition are significant factors. Furthermore, a synergistic interaction between α-synuclein and Aβ accumulation has been found both in vitro 6, 7, 12 and in transgenic mice models, 13, 14 with concurrent evidence that Aβ promotes α-synuclein fibrillization and thus may influence the progression of cognitive decline. 14 A therapy that prevents Aβ aggregation could conceivably be effective in the prevention or delay of Aβ-associated neurotoxicity. A new class of small molecules, structurally related to apomorphine, prevent Aβ fibril formation in vivo and undergo rapid autoxidation, suggesting that these autoxidation products may inhibit Aβ fibrillization. 15 More recently, transgenic Alzheimer disease (AD) mouse models treated with apomorphine demonstrated improvements in short-term memory function and significant reductions in intraneuronal Aβ accumulation, possibly due to antioxidative stress mechanisms. 16 Given the role of Aβ aggregation in the etiology of PDD and the use of apomorphine in the management of motor complications in PD, we sought to determine whether apomorphine may have anti-amyloid effects in a clinicopathological study. We hypothesized that non-demented PD subjects who had received apomorphine ante-mortem would have reduced Aβ burden compared to a matched group who had not received this treatment.
Materials and Methods

Case selection
Forty three PD cases with exposure to apomorphine in life (Apo+) diagnosed using accepted neuropathological criteria 17 were identified from donors to Queen Square Brain Bank for Neurological Disorders, University College London. Apomorphine naïve cases (Apo-, n=38) were matched to age at disease onset, disease duration and age at death. Presence or absence of dementia was determined retrospectively by review of case notes and agreed by consensus of movement disorder specialists (A.J.Y, H.L., D.J.B.), according to established criteria. 18 Specifically, cognitive deficits severe enough to impact on activities of daily living, with a neuropsychological assessment (if available) was considered a positive history for PDD. 18 Other data collected included dose (early (within one month of commencement), one year, maximum dose), duration and method of delivery of apomorphine therapy; anticholinergic drug exposure (a potential confounder 19 ); dopaminergic medication use; and clinical and demographic data. Lifetime cumulative levodopa dose was calculated using a previously described method. 20 An approximation for cumulative apomorphine dose was calculated using the following equation, approximating to the area under the curve: ((early apomorphine dose (mg) + one year dose)/2*1 + (one year + maximum apomorphine dose)/2*(duration of apomorphine use (years)-1))*365.25. All study subjects provided written informed consent ante-mortem. Cases were collected using a protocol approved by London Multicentre Research Ethics Committee and stored under the Human Tissue Authority licence.
Tissue collection
After fixation in 10% buffered formalin, brains were examined by a neuropathologist in accordance with QSBB protocol. Seven μm thick paraffin sections were cut and de-paraffinized, followed by pretreatment with formic acid and pressure-cooking in citrate buffer at pH 6.0 and stained according to previously published methods. 21 Nonspecific binding was blocked using 10% non-fat milk in phosphate-buffered saline. Sections were incubated with antibodies recognizing Aβ, residues [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] (Biosource Int, 1:4,000), α-synuclein (Novocastra, 1:75) or tau (AT8, Autogen Bioclear, 1:600). The secondary antibody (Dako, 1:200) was then applied, followed by incubation with ABC (Dako) and colour development by di-aminobenzidine/H2O2.
Quantification of pathology
The frequency of neocortical Aβ-positive plaques (mature and diffuse) was assessed using Aβ immunohistochemistry (performed by T.L., Y.C. and T.R., blinded to clinical data) using a previously described protocol. 7, 22 Using the approach recommended by CERAD, the severity of the cortical pathology for each plaque type was determined in a semi-quantitative manner as absent (grade 0), sparse (1), moderate (2) or frequent (3) for the following regions: frontal, temporal, occipital and parietal cortices; and entorhinal cortex. 7 Scores for both mature (Plaquesum, range 0-15) and diffuse (Diffusesum, range 0-15) plaques were calculated, in addition to total Aβ plaque score (Plaquesum+Diffusesum, range 0-30). α-synuclein pathology was assessed using a semi-quantitative grading system 23 and Braak LB pathology stage was given for each case based on the distribution of LB.
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A previously described and validated quantitative method was also used for determining the Aβ cortical load and LB counts. 7, 8 As we have previously found a good correlation between the cingulate and entorhinal LB densities and total cortical LB densities (Spearman's r = 0.985), and between temporal and parietal Aβ scores and total cortical Aβ scores (Spearman's r = 0.975), 7 using image analysis LB densities and Aβ load were also determined in these anatomical areas. Regions of interest were outlined and the surface area of each section measured using the NIH Image J software (available at http://rsb.info.nih.gov/ij/applets.html). In the selected areas all LBs were systematically counted and LB counts, adjusted to surface area, were expressed as LBs/mm 2 , with Aβ load density expressed/ mm 2 . Intra-and inter-rater repeatability studies revealed that 95% of measurements fell within two standard deviations of the mean difference, with a correlation coefficient of 0.996.
Cerebral amyloid angiopathy (CAA) was quantified based on a 4-tier grading system as described elsewhere 7 in the same cortical and subcortical regions. Using Aβ immunohistochemistry, the presence or absence of Aβ-positive plaques was also measured in different brain regions and a Thal phase allocated to each case. 25 Neurofibrillary tangle pathology was determined using Braak staging 26 and apolipoprotein E (APOE) genotype was determined for 24 Apo+ and 34 Apo-cases using previously described methods.
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Statistics
Subjects were classified by whether they had received apomorphine in life (Apo+) or not (Apo-) and cognitive status at the time of death (normal, CN, or impaired, CI), thus yielding four groups: Apo-CN, p= 0.179, Mann-Whitney 2-sided test).
Within the whole Apo+ group, early dose of apomorphine used tended to be greater in those who were cognitively normal compared to cognitively impaired at death but did not reach statistical significance (median dose 44 vs. 11 mg, p=0.093, Mann-Whitney 2-sided test). No significant differences were seen in one year dose, maximum dose, cumulative dose and duration of apomorphine in those who were cognitively normal. No difference in amyloid burden was seen in those using pen versus infusion delivery method, which is likely to be due to the small numbers within each group (data not shown). In the Apo+CN group only, a significant negative correlation was seen between maximum apomorphine dose received and Plaquesum+Diffusesum score (r= -0.474, p=0.047, Spearman's rho, Figure 1A ). Correlation between both maximum and early dose of apomorphine and Diffusesum score did not reach significance (r= -0.450, p=0.070 and r= -0.465, p=0.052, respectively, Spearman's rho, Figure 1B and 1C) . The analyses were repeated after removal of the obvious outlier (a case receiving a maximum dose of apomorphine 400mg). There was a significant association between early apomorphine dose and Diffusesum score (r= -0.504, p=0.046), with no significant correlation between maximum dose of apomorphine and Diffusesum score or Plaquesum+Diffusesum score (r= -0.431, p=0.084 and r= -0.444, p=0.076, respectively, Spearman's rho, Figure 1D and 1E).
To inform our selection of covariates that may predict Aβ in an explanatory model, we explored the association between Aβ score and gender, anticholinergic use, APOE status, age at disease onset, age at death, disease duration and cumulative levodopa dose (table 3) . Of these, only gender, APOE positivity and age at death were significantly associated. These covariates were therefore entered into a negative binomial model with Plaquesum+Diffusesum score of the CN group as the dependent and early/maximum/one year/cumulative apomorphine dose; age at death; APOE positivity; and gender as independent variables. Early and maximum dose were stable significant predictors of Plaquesum+Diffusesum score, with greater dose predicting reduced Aβ. The other dose calculations were not significant (table 3) .
Discussion
This is the first clinicopathological study to investigate the relationship between amyloid burden in PD subjects who had received apomorphine ante-mortem, following reports of putative diseasemodifying effects in AD murine models. 16 It is possible that apomorphine treatment may have a modifying effect on Aβ peptide deposition in non-demented PD cases, with our results demonstrating decreased diffuse and total plaque load in the Apo+ compared to Apo-group, reduced Aβ accumulation in subjects who had received greater earlier and maximum apomorphine doses and an inverse association between maximum drug dose and Aβ peptide deposition.
Mechanisms by which apomorphine may reduce Aβ accumulation include antioxidative prevention of apoptosis and synaptic injury, and greater degradation of intracellular Aβ, the latter potentially by upregulation of the proteasome system. 16 In vitro work indicating that apomorphine inhibits Aβ fibril formation and stabilizes Aβ oligomeric species via hydroxyl groups on the D-ring of apomorphine and related compounds adds further support to a mechanistic basis for the observed benefits. 15 Aβ42, containing 42 amino-acid residues, is a major constituent of mature amyloid plaques, and is highly prone to oligomerization and aggregation into fibrils. [29] [30] [31] Conversely, Aβ40 is not found within diffuse plaques, which are not fibrillar and contain almost exclusively Aβ42 proteins; these may represent precursors of mature, neuritic plaques. 31 Aβ42 is the more toxic of the species, 29 and hence we speculate that the positive findings in our study that relate to diffuse plaque and total plaque load may be attributable to apomorphine-induced inhibition of Aβ42 to a greater degree than Aβ40. This is substantiated by the observation that specifically it is diffuse plaque load which correlates with α-synuclein pathology. 7 The finding of lower Aβ burden in the Apo+CN compared to Apo-CN group is strengthened by the fact that the former cases had greater anticholinergic exposure, which has been associated with increased Aβ plaque densities. 19 However, this could also be explained by inadvertent sampling bias.
Postural instability gait difficulty (PIGD) phenotype is a recognised risk factor for the development of PDD 1, 32, 33 and has been associated with greater Aβ deposition than in tremor dominant subtypes, 34, 35 hence confounding-by-indication is a possibility. Anticholinergic drugs were previously used to treat tremor and hence anticholinergic use in this study may reflect a proxy for motor phenotype;
unfortunately the retrospective nature of this study meant that we were unable to account for motor heterogeneity.
Within the Apo+CN group, total α-synuclein load was smaller than in the Apo-CN group, which is of significance as cortical Aβ deposition and LB load demonstrate a close association in Lewy body diseases 6, 7, 11 and may have contributed to the greater amyloid plaque burden in the Apo-CN cases.
Moreover, recent studies have suggested that cortical LB pathology may be the principal pathological substrate of dementia in PD. 9, 10 No differences were seen in α-synuclein load however, when analysis was limited to those cases where APOE status was available (supplementary table 1); significantly reduced Aβ deposition remained between the cognitively normal and impaired groups, thus strengthening our findings. One study has previously demonstrated an association between tau pathology and cerebrovascular disease, with greater cerebrovascular lesion burden in PDD cases compared to age-matched controls. 36 Others, however, have shown that cerebrovascular burden occurs in only a minority 3, 9, 37 and is not a significant predictor of cognitive impairment. 10 We believe that cerebrovascular disease is therefore unlikely to contribute to dementia in PD in a majority of patients.
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In contrast to AD mouse models, 16 we did not find differences in tau pathology between those who had and had not received apomorphine, which may represent differing underlying disease processes.
It is interesting that differences were only seen within the cognitively normal group and not in those with dementia at the time of death. Indeed, although significance was not reached, those in the Apo+CI group tended to have higher Aβ plaque densities than Apo-CI cases (table 2) ; we hypothesize that when apomorphine was stopped in the cognitively impaired group there may have been acceleration of Aβ deposition, or that the doses used in this population were insufficient to inhibit Aβ fibril formation. 15 We note, however, that overall there were no differences in median doses of apomorphine between the groups, although those who were cognitively normal tended to have a higher early dose. It is noteworthy that murine models used 5 to 10mg/kg of apomorphine per week (corresponding to 0.4-0.8mg/kg in humans) 16 and whilst not reaching significance, the Apo+CN group in our study tended towards greater early, one year and maximum doses of apomorphine.
Additionally, in vitro work has indicated that if apomorphine was added to cell culture after the neurotoxic insult, the antioxidant effect of the drug was significantly lessened; 39 hence we speculate that apomorphine may have been commenced in the Apo+CI after the deposition of toxic Aβ and/or LB species and thus too late to observe a clinical effect.
Although this study has yielded some promising results, the data are exploratory and clearly require confirmation in larger cohorts and in vivo. We acknowledge that one-tailed statistics, used due to the hypothesis-driven study, without correction for multiple hypotheses, could possibly render the associations observed as due to chance. However, the fact that greater apomorphine doses remained a significant predictor of Aβ load in a model after adjusting for other covariates adds consistency and strength to our argument, as do the two-tailed Spearman's correlations. The study design at present cannot answer whether apomorphine prevents cognitive impairment, and would necessitate a 
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